Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood.
from Reuters: Health https://ift.tt/2wR25Vg
No comments:
Post a Comment